Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06297525 · ClinicalTrials.gov registry record · Phase 1
Study of STP938 in Advanced Solid Tumours
A Phase 1 study of Solid Tumor, sponsored by Step Pharma, SAS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT06297525 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Step Pharma, SAS. The registered enrollment target is 70 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT06297525, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Step Pharma, SAS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
Conditions Studied
Interventions
- DRUG STP938
Study Locations (7)
Other
- The Beatson Institute for Cancer Research - Glasgow
- University College London - London
- The Christie - Manchester
Texas
- Mary Crowley Cancer Research Center - Dallas
- Next Oncology - San Antonio
Florida
- Comprehensive Hematology Oncology, LLC - St. Petersburg
Paris
- Institut Gustave Roussy - Villejuif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-08-02 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06297525
The ClinicalTrials.gov registry entry for NCT06297525 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (68% lower). The listed sponsor is Step Pharma, SAS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which STP938 is the first listed.
NCT06297525 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT06297525 about?
NCT06297525 is a clinical study titled "Study of STP938 in Advanced Solid Tumours". The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.
What is the current status of trial NCT06297525?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-08-02. Estimated completion is 2027-05.
What conditions does trial NCT06297525 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06297525?
The interventions under investigation include: STP938 (DRUG).
Who is sponsoring clinical trial NCT06297525?
This trial is sponsored by Step Pharma, SAS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06297525 being conducted?
This trial has 7 study locations across Florida, Texas, Paris. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.